tiprankstipranks
Trending News
More News >
Shandong Xinhua Pharmaceutical Company Limited Class H (HK:0719)
:0719
Advertisement

Shandong Xinhua Pharmaceutical Company Limited Class H (0719) Stock Statistics & Valuation Metrics

Compare
2 Followers

Total Valuation

Shandong Xinhua Pharmaceutical Company Limited Class H has a market cap or net worth of HK$10.13B. The enterprise value is HK$5.41B.
Market CapHK$10.13B
Enterprise ValueHK$5.41B

Share Statistics

Shandong Xinhua Pharmaceutical Company Limited Class H has 195,000,000 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding195,000,000
Owned by Insiders
Owned by Institutions

Financial Efficiency

Shandong Xinhua Pharmaceutical Company Limited Class H’s return on equity (ROE) is 0.09 and return on invested capital (ROIC) is 7.16%.
Return on Equity (ROE)0.09
Return on Assets (ROA)0.05
Return on Invested Capital (ROIC)7.16%
Return on Capital Employed (ROCE)0.09
Revenue Per Employee1.16M
Profits Per Employee66.71K
Employee Count7,296
Asset Turnover0.94
Inventory Turnover5.05

Valuation Ratios

The current PE Ratio of Shandong Xinhua Pharmaceutical Company Limited Class H is 11.1. Shandong Xinhua Pharmaceutical Company Limited Class H’s PEG ratio is ―.
PE Ratio11.1
PS Ratio
PB Ratio
Price to Fair Value0.75
Price to FCF
Price to Operating Cash Flow21.34
PEG Ratio

Income Statement

In the last 12 months, Shandong Xinhua Pharmaceutical Company Limited Class H had revenue of 8.47B and earned 470.02M in profits. Earnings per share was 0.69.
Revenue8.47B
Gross Profit2.04B
Operating Income534.37M
Pretax Income533.65M
Net Income470.02M
EBITDA1.11B
Earnings Per Share (EPS)0.69

Cash Flow

In the last 12 months, operating cash flow was 234.13M and capital expenditures -76.81M, giving a free cash flow of 207.96M billion.
Operating Cash Flow234.13M
Free Cash Flow207.96M
Free Cash Flow per Share1.07

Dividends & Yields

Shandong Xinhua Pharmaceutical Company Limited Class H pays an annual dividend of HK$0.273, resulting in a dividend yield of 4.01%
Dividend Per ShareHK$0.273
Dividend Yield4.01%
Payout Ratio40.42%
Free Cash Flow Yield
Earnings Yield

Stock Price Statistics

Beta0.75
52-Week Price Change43.81%
50-Day Moving Average7.78
200-Day Moving Average6.12
Relative Strength Index (RSI)40.74
Average Volume (3m)5.56M

Important Dates

Shandong Xinhua Pharmaceutical Company Limited Class H upcoming earnings date is Oct 23, 2025, TBA (Confirmed).
Last Earnings DateAug 26, 2025
Next Earnings DateOct 23, 2025
Ex-Dividend DateJun 27, 2025

Financial Position

Shandong Xinhua Pharmaceutical Company Limited Class H as a current ratio of 1.33, with Debt / Equity ratio of 14.53%
Current Ratio1.33
Quick Ratio0.88
Debt to Market Cap0.36
Net Debt to EBITDA0.10
Interest Coverage Ratio13.45

Taxes

In the past 12 months, Shandong Xinhua Pharmaceutical Company Limited Class H has paid 46.94M in taxes.
Income Tax46.94M
Effective Tax Rate0.09

Enterprise Valuation

Shandong Xinhua Pharmaceutical Company Limited Class H EV to EBITDA ratio is 3.44, with an EV/FCF ratio of 24.69.
EV to Sales0.45
EV to EBITDA3.44
EV to Free Cash Flow24.69
EV to Operating Cash Flow10.42

Balance Sheet

Shandong Xinhua Pharmaceutical Company Limited Class H has HK$1.28B in cash and marketable securities with HK$744.68M in debt, giving a net cash position of -HK$530.33M billion.
Cash & Marketable SecuritiesHK$1.28B
Total DebtHK$744.68M
Net Cash-HK$530.33M
Net Cash Per Share-HK$2.72
Tangible Book Value Per ShareHK$6.82

Margins

Gross margin is 21.34%, with operating margin of 6.31%, and net profit margin of 5.55%.
Gross Margin21.34%
Operating Margin6.31%
Pretax Margin6.30%
Net Profit Margin5.55%
EBITDA Margin13.16%
EBIT Margin6.77%

Analyst Forecast

The average price target for Shandong Xinhua Pharmaceutical Company Limited Class H is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target
Price Target Upside
Analyst Consensus
Analyst Count0
Revenue Growth Forecast2.32%
EPS Growth Forecast-14.41%

Scores

Smart Score6
AI Score70
What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis